Aleksandr V. Sokolov

Aleksandr V. Sokolov

Auto-generated profile, based on publicly available information

Aleksandr V. Sokolov

Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
JLJavier Sánchez Lorente
Javier Sánchez Lorente
ASAleksandr V. Sokolov
Aleksandr V. Sokolov
GFGavin Ferguson
Gavin Ferguson
HSHelgi B. Schiöth
Helgi B. Schiöth
AHAlexander S. Hauser
Alexander S. Hauser
DGDavid E. Gloriam
David E. Gloriam

31 July 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ENEugenia D. Namiot
Eugenia D. Namiot
DSDiana Smirnovová
Diana Smirnovová
ASAleksandr V. Sokolov
Aleksandr V. Sokolov
VCVladimir N. Chubarev
Vladimir N. Chubarev
VTVadim V. Tarasov
Vadim V. Tarasov
HSHelgi Schiöth
Helgi Schiöth
Major depressive disorder (MDD), commonly known as depression, affects over 300 million people worldwide as of 2018 and presents a wide range of clinical symptoms. The international clinical trials registry platform (ICTRP) introduced by WHO includes aggregated data from ClinicalTrials.gov and 17 other national registers, making it the largest clinical trial platform. Here we analysed data in ICTRP with the aim of providing comprehensive insights into clinical trials on depression. Applying a novel hidden duplicate identification method, 10,606 depression trials were identified in ICTRP, with ANZCTR being the largest non- ClinicalTrials.gov database at 1031 trials, followed by IRCT with 576 trials, ISRCTN with 501 trials, CHiCTR with 489 trials, and EUCTR with 351 trials. The top four most studied drugs, ketamine, sertraline, duloxetine, and fluoxetine, were consistent in both groups, but ClinicalTrials.gov had more trials for each drug compared to the non-ClinicalTrials.gov group. Out of 9229 interventional trials, 663 unique agents were identified, including approved drugs (74.5%), investigational drugs (23.2%), withdrawn drugs (1.8%), nutraceuticals (0.3%), and illicit substances (0.2%). Both ClinicalTrials.gov and non-ClinicalTrials.gov databases revealed that the largest categories were antidepressive agents (1172 in ClinicalTrials.gov and 659 in non-ClinicalTrials.gov) and nutrients, amino acids, and chemical elements (250 in ClinicalTrials.gov and 659 in non-ClinicalTrials.gov), indicating a focus on alternative treatments involving dietary supplements and nutrients. Additionally, 26 investigational antidepressive agents targeting 16 different drug targets were identified, with buprenorphine (opioid agonist), saredutant (NK2 antagonist), and seltorexant (OX2 antagonist) being the most frequently studied. This analysis addresses 40 approved drugs for depression treatment including new drug classes like GABA modulators and NMDA antagonists that are offering new prospects for treating MDD, including drug-resistant depression and postpartum depression subtypes.

15 July 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ASAleksandr V. Sokolov
Aleksandr V. Sokolov
HSHelgi Schiöth
Helgi Schiöth
The causes of depression are complex, and the current diagnosis methods rely solely on psychiatric evaluations with no incorporation of laboratory biomarkers in clinical practices. We investigated the stability of blood DNA methylation depression signatures in six different populations using six public and two domestic cohorts (n = 1942) conducting mega-analysis and meta-analysis of the individual studies. We evaluated 12 machine learning and deep learning strategies for depression classification both in cross-validation (CV) and in hold-out tests using merged data from 8 separate batches, constructing models with both biased and unbiased feature selection. We found 1987 CpG sites related to depression in both mega- and meta-analysis at the nominal level, and the associated genes were nominally related to axon guidance and immune pathways based on enrichment analysis and eQTM data. Random forest classifiers achieved the highest performance (AUC 0.73 and 0.76) in CV and hold-out tests respectively on the batch-level processed data. In contrast, the methylation showed low predictive power (all AUCs < 0.57) for all classifiers in CV and no predictive power in hold-out tests when used with harmonized data. All models achieved significantly better performance (>14% gain in AUCs) with pre-selected features (selection bias), with some of the models (joint autoencoder-classifier) reaching AUCs of up to 0.91 in the final testing regardless of data preparation. Different algorithmic feature selection approaches may outperform limma, however, random forest models perform well regardless of the strategy. The results provide an overview over potential future biomarkers for depression and highlight many important methodological aspects for DNA methylation-based depression profiling including the use of machine learning strategies.

31 March 2026 in Translational Psychiatry
Verified
Journal Article
Open access
ASAleksandr V. Sokolov
Aleksandr V. Sokolov
MLMuataz S. Lafta
Muataz S. Lafta
JJJussi Jokinen
Jussi Jokinen
HSHelgi Schiöth
Helgi Schiöth
Suicide remains a critical global public health issue, accounting for nearly one million deaths annually and imposing profound societal and economic burdens. Despite its urgency, the lack of diagnostic and predictive biomarkers continues to hinder the development of effective prevention and treatment strategies. This study presents a comprehensive meta-analysis that integrates publicly available postmortem brain transcriptomic datasets and a domestic cohort, encompassing 16 cohorts. The transcriptomic data, sourced from the Gene Expression Omnibus repository, were generated using various techniques, including traditional RNA sequencing, microarray methods, and single-cell RNA sequencing. Differential expression analyses were performed across multiple brain regions, with meta-analyses stratified by cortical regions, the dorsolateral prefrontal cortex (DLPFC), and combined. We further analyzed whether covariates may affect the identified genes. Three meta-analytic approaches were employed, complemented by pathway and cell-set enrichment analyses. The unadjusted meta-analysis consistently identified several genes with altered expression, including upregulated P2RY12, CX3CR1, and GPR34, and downregulated SOX9 and PMP2, all at nominal significance. Additionally, multiple genes encoding long non-coding RNAs (lncRNAs) exhibited nominally altered expression in suicide, including RP5-837J1.4, AC159540.14, DNM1P47, AC004158.2, EEF1A1P30, and RP11-339B21.8. Several alternative strategies to run meta-analysis were performed and moderators were investigated. Cell-type-specific expression deconvolution and meta-analysis identified several genes overlapping with bulk expression meta-analysis, and genes were attributed to neuronal lineages. These findings highlight plausible molecular targets for future validation studies, suggesting the involvement of microglia (P2RY12 and CX3CR1), astrocytes (SOX9), immune responses (GPR34), myelin regulation (PMP2), and epigenetic modulation via lncRNAs. This research advances the understanding of the molecular architecture of suicide and provides a foundation for future studies focused on targeted prevention and therapeutic interventions.

1 September 2026 in Briefings in Bioinformatics
Verified
Journal Article
Open access
MKMikhail M. Khandokhin
Mikhail M. Khandokhin
ASAleksandr Sokolov
Aleksandr Sokolov
NONikolay Oskolkov
Nikolay Oskolkov
RFRobert Fredriksson
Robert Fredriksson
OTOlga E Titova
Olga E Titova
HSHelgi Schiöth
Helgi Schiöth
Public repositories now accumulate an unprecedented amount of metabolomics data. Despite the opportunities for large-scale meta-analyses opened by these repositories, the deposited data rarely becomes systematically re-analyzed. We conducted a systematic metadata-based re-analysis of all human blood metabolomics studies in the Metabolomics Workbench performed using Orbitrap or QTOF mass spectrometry, encompassing 44 165 samples. After harmonizing metabolites with PubChem identifiers and embedding them using SMILES representations, we generated a map of 6752 blood metabolites forming 25 structural clusters, and subsequently performed correlation analysis between these clusters, biomarkers, and drugs. Analysis of 337 120 metabolite pairs detected in at least 10 studies showed that structurally related clusters display correlated abundances (ρ up to 0.6). Correlation patterns among established clinical biomarkers revealed candidate metabolic correlates, several with ρ > 0.7. We also developed open-source software enabling similar analyses for any metabolite across the Workbench data explored. Additionally, curating drug-containing datasets enabled meta-analyses for compounds such as acetaminophen, metoprolol, and atenolol, identifying both known and novel metabolic signatures. Besides the biological insights, we have found that Orbitrap and QTOF tend to detect different metabolites, but they give quantitatively coherent results on overlapping compounds. Overall, the present study provides the methodology and software to perform large-scale mining of public metabolomics data enabling its re-analysis to obtain novel biomedical insights.